Alan W. Partin, M.D., Ph.D.
Jakurski Family Director
Urologist-in-Chief, The Johns Hopkins Hospital
Director, Department of Urology
Professor, Urology, Oncology and Pathology
Dr. Alan W. Partin is the author or co-author of more than 550 scientific articles, serves on numerous editorial boards, is editor-in-chief of Urology Case Reports and is editor of the Campbell-Walsh Urology text. He has been honored with many awards, including the Johns Hopkins Young Investigators’ Day Award, the Pfizer Scholars in Urology award in 1996 and the Gold Cystoscope award in 2001. In 2004, Dr. Partin was named director of the Department of Urology at the Brady Urological Institute and urologist-in-chief of The Johns Hopkins Hospital.
Dr. Partin is an expert in assessing prognosis and making predictions for men with prostate cancer. The creation of the Partin Tables, which can predict with 95 percent accuracy a man’s likelihood of being cured by treatment, made his research famous. Dr. Partin’s laboratories and clinical and surgical interests focus on developing and testing new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. His laboratories have investigated many new PSA-like serum tests, many of which have subsequently become available for clinical utilization. He also has an academic and clinical interest in the basic science investigation of novel proteins that may help in detection and staging of prostate cancer.
Dr. Partin earned his undergraduate degree in chemistry from the University of Mississippi, where he was an Academic All-America football player. He received his M.D. and his Ph.D. in pharmacology and molecular sciences from The Johns Hopkins University, where he continued his postdoctoral training.
Kenneth J. Pienta, M.D.
The Donald S. Coffey Professor of Urology
Professor, Oncology, Pharmacology and Molecular Sciences
Dr. Kenneth J. Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology and of pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. He is a two-time American Cancer Society Clinical Research Professor Award recipient. He serves as the director of research for the Brady Urological Institute.
Dr. Pienta has international expertise in the development of novel chemotherapeutic programs for prostate cancer. He has championed the concept that translational research is often best accomplished by multidisciplinary teams of scientists and clinicians. The success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007.
He is the author of more than 300 peer-reviewed articles and has been the principal investigator on numerous local and national clinical trials. Throughout his career, Dr. Pienta has effectively mentored over 40 students, residents and fellows to successful careers in medicine.